Virtual Library

Start Your Search

O. Frenkel

Author of

  • +

    Poster Display session (Friday) (ID 65)

    • Event: ELCC 2018
    • Type: Poster Display session
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 4/13/2018, 12:30 - 13:00, Hall 1
    • +

      150P - Correlation between erlotinib-induced rash and efficacy in first-line therapy of patients with advanced non-small cell lung cancer (NSCLC) expressing epidermal growth factor receptor (EGFR)-mutation: A prospective, multi-center, open-label, single-arm, phase II study (ID 408)

      12:30 - 13:00  |  Author(s): O. Frenkel

      • Abstract
      • Slides

      Skin rash is the most common adverse event following erlotinib treatment, reported in about 75% of patients. Several retrospective analyses have suggested that erlotinib-induced skin rash may be associated with better therapeutic outcomes. This phase II TIME (Tarceva In Mutated EGFR patients) study assessed the relationship between erlotinib-induced rash and clinical efficacy in EGFR-mutated advanced NSCLC patients receiving erlotinib first line.

      Patients ≥18 years of age, with EGFR mutated stage IV or inoperable stage IIIB NSCLC, previously untreated with any systemic anti-neoplastic therapy for their advanced stage disease, were enrolled to receive oral erlotinib at an initial daily dose of 150 mg until disease progression or unacceptable toxicity. The primary endpoint was progression-free survival (PFS) according to rash grade.

      Sixty patients (41 women, 19 men; median age, 70.7 years) were enrolled in 12 medical centers across Israel. Median PFS from the time of enrollment was 10.4 months (95% CI, 7.5–15.3). The incidence of grade 0, 1, 2, and 3 rash was 6.8%, 22.0%, 39.0% and 32.2%, respectively. Kaplan Meier survival analysis showed that patients with grade 2–3 rash had a statistically significant longer median PFS of 12.0 months (95% CI, 9.3–17.1) compared to patients with grade 0–1 rash who had a median PFS of 5.0 months (95% CI, 2.0–13.5), hazard ratio = 0.38, (95% CI, 0.20–0.71; p = 0.002). Similar results were observed in differentiation between exon 19 and exon 21 mutations.

      Albeit a relatively small sample of patients, the results of this prospective study strongly indicate that skin rash during treatment with erlotinib represents a significant predictive factor of efficacy in patients treated for advanced stage NSCLC. These results support previously published retrospective data. Patients might be reassured that rash severity indicates response to treatment. Moreover, an absence of rash as a response to treatment might be a negative prognostic factor in this group of patients.

      Clinical trial identification: ID: NCT01174563

      Legal entity responsible for the study:
      Roche Pharmaceuticals (Israel) LTD

      Roche Pharmaceuticals (Israel) LTD

      M. Gottfried: Advisory Board and corporate sponsored research: Pfizer, BI, MSD, BMS, Roche, AZ, Abbvie. S. Keren Rosenberg: Advisory Boards: Roche, Pfizer, MSD, AZ, BI, Takeda Corporate-sponsored research: Roche. J. Dudnik: Advisory Boards: BI, Astra-Zeneca Corporate-sponsored studies: Roche, Astra-Zeneca, MSD, BMS, BI. M. Wollner: Corporate-sponsored research and consultations fees: Roche, MSD, BMS, AZ, BI, Pfizer Consultation fee: Takeda. J. Bar: Corporate-sponsored research: BI, AZ, Pfizer, Merck, Abbvie, Roche, AZ, MSD, BMS, BI Consulting fees: Roche, Pfizer, Takeda, Abbvie, VBL, BI, AZ, MSD, BMS. A. Onn: Advisory Board: Roche, BI, AZ, MSD. O. Frenkel: Employee of Roche Pharmaceuticals (Israel) Ltd. N. Maimon: Corporate-sponsored research: Roche, MSD, AZ, BI, Pfizer, Abbvie, BMS.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.